BIOMAT Database Logo BIOMAT Database Logo

Multicenter study of trilostane: a new hormonal agent in advanced postmenopausal breast cancer. 1987

C J Williams, and V Barley, and G Blackledge, and A Hutcheon, and S Kaye, and D Smith, and C Keen, and D J Webster, and C Rowland, and C Tyrrell
Department of Medical Oncology, Southampton General Hospital, United Kingdom.

Trilostane, an inhibitor of the production of adrenal estrogens, was administered, together with dexamethasone, to 97 eligible postmenopausal women with advanced breast cancer. Seventy-four patients who had either received trilostane for a minimum of 10 weeks or whose disease had progressed while on trilostane before this period were assessed for tumour response. Eighteen patients (25%) had objective responses (two complete, 16 partial); a further 21 patients had stable disease. The response rate among all 97 patients, including those not treated for a minimum 10-week period, was 19%. Thirty-two of 97 patients reported adverse reactions which were attributed to trilostane and/or dexamethasone. Therapy was stopped for 15 patients, and the dose of trilostane was reduced for ten. Diarrhea was the commonest side effect, being reported in 16 patients, of whom nine stopped treatment. Trilostane, given with a corticosteroid, is an effective alternative hormonal agent acting by adrenal blockade for postmenopausal women with advanced breast cancer.

UI MeSH Term Description Entries
D008593 Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age. Change of Life, Female
D009096 Multi-Institutional Systems Institutional systems consisting of more than one health facility which have cooperative administrative arrangements through merger, affiliation, shared services, or other collective ventures. Multi-Hospital Systems,Multi-Institutional System,Multihospital Systems,System, Multi-Hospital,System, Multi-Institutional,Systems, Multi-Institutional,Multi Hospital Systems,Multi Institutional System,Multi Institutional Systems,Multi-Hospital System,Multihospital System,System, Multi Hospital,System, Multi Institutional,System, Multihospital,Systems, Multi Institutional,Systems, Multi-Hospital,Systems, Multihospital
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas
D003907 Dexamethasone An anti-inflammatory 9-fluoro-glucocorticoid. Hexadecadrol,Decaject,Decaject-L.A.,Decameth,Decaspray,Dexasone,Dexpak,Hexadrol,Maxidex,Methylfluorprednisolone,Millicorten,Oradexon,Decaject L.A.
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013196 Dihydrotestosterone A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE. 5 alpha-Dihydrotestosterone,Androstanolone,Stanolone,17 beta-Hydroxy-5 beta-Androstan-3-One,17beta-Hydroxy-5alpha-Androstan-3-One,5 beta-Dihydrotestosterone,5-alpha Dihydrotestosterone,5-alpha-DHT,Anaprotin,Andractim,Dihydroepitestosterone,Gelovit,17 beta Hydroxy 5 beta Androstan 3 One,17beta Hydroxy 5alpha Androstan 3 One,5 alpha DHT,5 alpha Dihydrotestosterone,5 beta Dihydrotestosterone,Dihydrotestosterone, 5-alpha,beta-Hydroxy-5 beta-Androstan-3-One, 17

Related Publications

C J Williams, and V Barley, and G Blackledge, and A Hutcheon, and S Kaye, and D Smith, and C Keen, and D J Webster, and C Rowland, and C Tyrrell
Trilostane in advanced breast cancer.
December 2006, Expert opinion on pharmacotherapy,
C J Williams, and V Barley, and G Blackledge, and A Hutcheon, and S Kaye, and D Smith, and C Keen, and D J Webster, and C Rowland, and C Tyrrell
Hormonal changes in postmenopausal women with breast cancer treated with trilostane and dexamethasone.
October 1985, Clinical endocrinology,
C J Williams, and V Barley, and G Blackledge, and A Hutcheon, and S Kaye, and D Smith, and C Keen, and D J Webster, and C Rowland, and C Tyrrell
Trilostane therapy for advanced breast cancer.
April 1985, Cancer treatment reports,
C J Williams, and V Barley, and G Blackledge, and A Hutcheon, and S Kaye, and D Smith, and C Keen, and D J Webster, and C Rowland, and C Tyrrell
Trilostane in the treatment of advanced breast cancer.
January 1983, Cancer chemotherapy and pharmacology,
C J Williams, and V Barley, and G Blackledge, and A Hutcheon, and S Kaye, and D Smith, and C Keen, and D J Webster, and C Rowland, and C Tyrrell
Droloxifene, a new antiestrogen. Hormonal influences in postmenopausal breast cancer patients.
January 1991, American journal of clinical oncology,
C J Williams, and V Barley, and G Blackledge, and A Hutcheon, and S Kaye, and D Smith, and C Keen, and D J Webster, and C Rowland, and C Tyrrell
[New developments in the hormonal treatment of breast cancer in postmenopausal women].
October 1999, Bulletin du cancer,
C J Williams, and V Barley, and G Blackledge, and A Hutcheon, and S Kaye, and D Smith, and C Keen, and D J Webster, and C Rowland, and C Tyrrell
Fulvestrant ('Faslodex')--a new hormonal treatment for advanced breast cancer.
January 2004, European journal of oncology nursing : the official journal of European Oncology Nursing Society,
C J Williams, and V Barley, and G Blackledge, and A Hutcheon, and S Kaye, and D Smith, and C Keen, and D J Webster, and C Rowland, and C Tyrrell
A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer.
January 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
C J Williams, and V Barley, and G Blackledge, and A Hutcheon, and S Kaye, and D Smith, and C Keen, and D J Webster, and C Rowland, and C Tyrrell
Breast cancer risk with postmenopausal hormonal treatment.
January 2005, Human reproduction update,
C J Williams, and V Barley, and G Blackledge, and A Hutcheon, and S Kaye, and D Smith, and C Keen, and D J Webster, and C Rowland, and C Tyrrell
[Hormonal therapy in advanced breast cancer].
December 1949, Der Krebsarzt,
Copied contents to your clipboard!